131 related articles for article (PubMed ID: 8864638)
1. What kind of cardiovascular alterations could be influenced positively by oral antidiabetic agents?
Pogátsa G
Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S27-31. PubMed ID: 8864638
[TBL] [Abstract][Full Text] [Related]
2. Potassium channels in the cardiovascular system.
Pogátsa G
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S91-8. PubMed ID: 8529523
[TBL] [Abstract][Full Text] [Related]
3. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?
Leibowitz G; Cerasi E
Diabetologia; 1996 May; 39(5):503-14. PubMed ID: 8739909
[TBL] [Abstract][Full Text] [Related]
4. Glibenclamide, a new sulphonylurea: whither oral hypoglycaemic agents?
Marble A
Drugs; 1971; 1(2):109-15. PubMed ID: 4999930
[No Abstract] [Full Text] [Related]
5. Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
Langtry HD; Balfour JA
Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345
[TBL] [Abstract][Full Text] [Related]
6. New trends in the development of oral antidiabetic drugs.
Kecskemeti V; Bagi Z; Pacher P; Posa I; Kocsis E; Koltai MZ
Curr Med Chem; 2002 Jan; 9(1):53-71. PubMed ID: 11860348
[TBL] [Abstract][Full Text] [Related]
7. Influence of hypoglycaemic sulphonylureas on the electrophysiological parameters of the heart.
Koltai MZ
Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S15-20. PubMed ID: 8864636
[TBL] [Abstract][Full Text] [Related]
8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
9. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
10. The effect of sulphonylurea therapy on the outcome of coronary heart diseases in diabetic patients.
Pogatsa G; Koltai MZ; Jermendy G; Simon J; Aranyi Z; Ballagi-Pordany G
Acta Med Hung; 1992-1993; 49(1-2):39-51. PubMed ID: 1296186
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy of glibenclamide and glimepiride in reperfusion-induced arrhythmias in rats.
El-Reyani NE; Bozdogan O; Baczkó I; Leprán I; Papp JG
Eur J Pharmacol; 1999 Jan; 365(2-3):187-92. PubMed ID: 9988102
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular effects of sulphonylurea derivatives.
Smits P; Bijlstra PJ; Russel FG; Lutterman JA; Thien T
Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S55-9. PubMed ID: 8864641
[TBL] [Abstract][Full Text] [Related]
13. Effect of glibenclamide and glimepiride treatment on the development of myocardial infarction in rats.
El-Reyani NE; Baczkó I; Leprán I; Papp JG
Acta Physiol Hung; 2000; 87(2):173-84. PubMed ID: 11205966
[TBL] [Abstract][Full Text] [Related]
14. [Pharma-clinics. Medication of the month. Glimepiride (Amarylle)].
Scheen AJ
Rev Med Liege; 2000 Mar; 55(3):184-6. PubMed ID: 10823010
[TBL] [Abstract][Full Text] [Related]
15. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction.
Zeller M; Danchin N; Simon D; Vahanian A; Lorgis L; Cottin Y; Berland J; Gueret P; Wyart P; Deturck R; Tabone X; Machecourt J; Leclercq F; Drouet E; Mulak G; Bataille V; Cambou JP; Ferrieres J; Simon T;
J Clin Endocrinol Metab; 2010 Nov; 95(11):4993-5002. PubMed ID: 20702526
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM?
Smits P; Thien T
Diabetologia; 1995 Jan; 38(1):116-21. PubMed ID: 7744216
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2.
Jackson JE; Bressler R
Drugs; 1981 Oct; 22(4):295-320. PubMed ID: 7030708
[No Abstract] [Full Text] [Related]
18. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
19. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA).
Meier JJ; Deifuss S; Klamann A; Schmiegel W; Nauck MA;
Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):344-50. PubMed ID: 14520601
[TBL] [Abstract][Full Text] [Related]
20. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits.
Nieszner E; Posa I; Kocsis E; Pogátsa G; Préda I; Koltai MZ
Exp Clin Endocrinol Diabetes; 2002 Aug; 110(5):212-8. PubMed ID: 12148084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
